CO-1.01

DRUG2 trials

Sponsors

Clovis Oncology, Inc.

Conditions

Metastatic Pancreatic Adenocarcinoma

Phase 2

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

CompletedNCT01124786

Clovis Oncology, Inc.Metastatic Pancreatic Adenocarcinoma

Start: 2010-05-31End: 2013-06-30Updated: 2014-04-17

Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

CompletedNCT01233375

Clovis Oncology, Inc.Metastatic Pancreatic Adenocarcinoma

Start: 2011-04-30End: 2013-03-31Updated: 2019-03-11

Related Papers

Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data

Journal of Cancer2021-01-0124 citations

Outcomes of Patients With Advanced Gastrointestinal Cancer in Relationship to Opioid Use: Findings From Eight Clinical Trials

Journal of the National Comprehensive Cancer Network2020-05-0110 citations

Outcomes of advanced gastrointestinal (GI) cancer patients in relationship to opioid use: An individual patient data pooled analysis from eight clinical trials.

Journal of Clinical Oncology2020-02-011 citations

Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies.

2018-11-2146 citations

Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real‐world study

Cancer Medicine2018-06-0140 citations

Development and validation of a prognostic nomogram for metastatic pancreatic cancer.

Journal of Clinical Oncology2018-05-20

Prediction of overall survival for metastatic pancreatic cancer treated with gemcitabine monotherapy: Development and external validation of a prognostic nomogram with open clinical trial data.

Journal of Clinical Oncology2018-02-01